WEBULL
News
KNSA
44.71
+0.81%
0.36
Weekly Report: what happened at KNSA last week (0202-0206)?
Weekly Report · 1d ago
Director Barry D. Quart Reports Disposal of Common Shares in Kiniksa Pharmaceuticals International plc
Reuters · 6d ago
Assessing Kiniksa Pharmaceuticals (KNSA) Valuation After Strong Earnings Growth And Accelerating Sales
Simply Wall St · 02/02 15:15
Weekly Report: what happened at KNSA last week (0126-0130)?
Weekly Report · 02/02 09:38
Citi Sticks to Its Buy Rating for Kiniksa Pharmaceuticals (KNSA)
TipRanks · 01/30 11:26
Does Rapid Earnings Growth and Upbeat Analyst Sentiment Change The Bull Case For Kiniksa (KNSA)?
Simply Wall St · 01/30 05:28
TD Cowen Remains a Buy on Kiniksa Pharmaceuticals (KNSA)
TipRanks · 01/29 12:26
Weekly Report: what happened at KNSA last week (0119-0123)?
Weekly Report · 01/26 09:38
Kiniksa: Arcalyst Is The Engine, But KPL-387 Is The Accelerator
Seeking Alpha · 01/24 05:40
Weekly Report: what happened at KNSA last week (0112-0116)?
Weekly Report · 01/19 09:41
Kiniksa Pharmaceuticals International (KNSA) Is Down 6.7% After Raising 2026 ARCALYST Revenue Outlook - Has The Bull Case Changed?
Simply Wall St · 01/15 02:33
Kiniksa Pharmaceuticals Reshapes Leadership With New COO, CSO
TipRanks · 01/14 22:00
Kiniksa Pharmaceuticals Appoints Ross Moat COO and Eben Tessari Chief Strategy Officer
Reuters · 01/14 21:31
Kiniksa Pharmaceuticals Is Maintained at Outperform by Wedbush
Dow Jones · 01/13 14:01
Kiniksa Pharmaceuticals Price Target Raised to $50.00/Share From $48.00 by Wedbush
Dow Jones · 01/13 14:01
Wedbush Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $50
Benzinga · 01/13 13:53
Kiniksa price target raised to $50 from $48 at Wedbush
TipRanks · 01/13 13:46
A Look At Kiniksa Pharmaceuticals (KNSA) Valuation After ARCALYST Update And Pipeline Progress
Simply Wall St · 01/13 12:20
Kiniksa Pharmaceuticals sees ARCALYST net product revenue between $900M-$920M for 2026
Seeking Alpha · 01/12 13:28
Kiniksa Pharmaceuticals Showcases Pipeline Progress and Cardiovascular Focus in New Corporate Presentation
Reuters · 01/12 13:06
More
Webull provides a variety of real-time KNSA stock news. You can receive the latest news about Kiniksa Pharmaceuticals International, plc through multiple platforms. This information may help you make smarter investment decisions.
About KNSA
Kiniksa Pharmaceuticals International, plc is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Its portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. Its ARCALYST is used for the treatment of recurrent pericarditis and reduces the risk of recurrence in adults and children 12 years and older. ARCALYST is also approved for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome, and the maintenance of remission in Deficiency of Interleukin-1 Receptor Antagonist. Its other portfolio includes KPL-387, KPL-1161, Abiprubart, and Mavrilimumab. Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha.